975 related articles for article (PubMed ID: 29065979)
1. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC
Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979
[TBL] [Abstract][Full Text] [Related]
2. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
[TBL] [Abstract][Full Text] [Related]
3. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.
Kehl KL; Yang S; Awad MM; Palmer N; Kohane IS; Schrag D
Cancer Immunol Immunother; 2019 Jun; 68(6):917-926. PubMed ID: 30877325
[TBL] [Abstract][Full Text] [Related]
4. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
Ghosh N; Tirpack A; Chan KK; Bass AR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
[TBL] [Abstract][Full Text] [Related]
5. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
Gu L; Khadaroo PA; Su H; Kong L; Chen L; Wang X; Li X; Zhu H; Zhong X; Pan J; Chen M
BMC Cancer; 2019 Jun; 19(1):559. PubMed ID: 31182049
[TBL] [Abstract][Full Text] [Related]
6. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
7. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.
Griewing LM; Schweizer C; Schubert P; Rutzner S; Eckstein M; Frey B; Haderlein M; Weissmann T; Semrau S; Gostian AO; Müller SK; Traxdorf M; Iro H; Zhou JG; Gaipl US; Fietkau R; Hecht M
BMC Cancer; 2021 Mar; 21(1):314. PubMed ID: 33761922
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
11. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
15. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
[TBL] [Abstract][Full Text] [Related]
16. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.
Park JA; Cheung NV
Cancer Treat Rev; 2017 Jul; 58():22-33. PubMed ID: 28622628
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers associated with checkpoint inhibitors.
Manson G; Norwood J; Marabelle A; Kohrt H; Houot R
Ann Oncol; 2016 Jul; 27(7):1199-206. PubMed ID: 27122549
[TBL] [Abstract][Full Text] [Related]
18. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
19. Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.
Iivanainen S; Koivunen JP
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952311
[TBL] [Abstract][Full Text] [Related]
20. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
